NCT00044746 is a Phase 4 clinical trial of Piperacillin/Tazobactam in Diabetes Mellitus, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Who is sponsoring NCT00044746?

NCT00044746 is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

What drugs are being tested in NCT00044746?

Interventions in NCT00044746: Piperacillin/Tazobactam.

What condition does NCT00044746 study?

NCT00044746 studies Diabetes Mellitus, Diabetic Foot.

Is NCT00044746 still recruiting?

NCT00044746 is currently completed. Last updated 7 February 2013.

Last reviewed 2013-02-07 · How we verify

NCT00044746

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients

Completed Phase 4 Last updated 7 February 2013

What this trial tests

Phase 4 trial testing Piperacillin/Tazobactam in Diabetes Mellitus in 314 participants. Completed in 1 January 2003.

Timeline

1 October 2000

Primary endpoint
1 January 2003

1 January 2003

Quick facts

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	314
Start date	1 October 2000
Primary completion	1 January 2003
Estimated completion	1 January 2003

Drugs / interventions tested

Piperacillin/Tazobactam

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →
Diabetic Foot — all drugs for Diabetic Foot →

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus or Diabetic Foot. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.
Zhang S, Liao X, Ding T, Ahn J. · · 2024 · cited 34× · PMID 38534695 · DOI 10.3390/antibiotics13030260

Verify or expand the search:

Other trials of Piperacillin/Tazobactam

Trials testing the same drug.

NCT06184659 — Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis · Phase 4 · recruiting
NCT06977347 — Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea · NA · not yet recruiting
NCT05753735 — eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF · Phase 2 · terminated
NCT04042077 — Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections · Phase 3 · terminated
NCT03441529 — A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Ora · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other Wyeth is now a wholly owned subsidiary of Pfizer trials

Trials by the same sponsor.

NCT00909688 — Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses · Phase 1 · completed
NCT00853749 — Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine · Phase 3 · completed
NCT00894634 — Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed
NCT00854009 — Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects · Phase 1 · completed
NCT00837837 — Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00044746 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wyeth is now a wholly owned subsidiary of Pfizer
Last refreshed: 7 February 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00044746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing